KALV Projected Dividend Yield
KalVista Pharmaceuticals Inc ( NASDAQ : KALV )KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has develop small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). Co. also is conducting preclinical development on an oral Factor XIIa inhibitor program, which Co. is initially improving to provide HAE therapeutics. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co. also is developing an oral disintegrating tablet formulation of sebetralstat. 20 YEAR PERFORMANCE RESULTS |
KALV Dividend History Detail KALV Dividend News KALV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |